Sven Tyge Langkjer

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study

Michael Andersson, Elisabeth Lidbrink, Karsten Bjerre et al. · Journal of Clinical Oncology · 2010 · 291 citations

Phase III Study of Intravenous Vinorelbine in Combination With Epirubicin Versus Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403)

Bent Ejlertsen, Henning T. Mouridsen, Sven Tyge Langkjer et al. · Journal of Clinical Oncology · 2004 · 59 citations

RELATION OF BLAST CELL SURVIVAL AND PROLIFERATION TO CHEMOTHERAPY RESISTANCE IN AML

Jan Maxwell Nørgaard, Sven Tyge Langkjer, Torben Palshof et al. · British Journal of Haematology · 1996 · 38 citations

MDR1 gene expression and drug resistance of AML cells

Jan Maxwell Nørgaard, Anne Bukh, Sven Tyge Langkjer et al. · British Journal of Haematology · 1998 · 34 citations · Full text

Hematological Malignancy, Mdr1 Expression, Medicine +13